Companies / Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

Nasdaq: OTLKCIK 1649989ISELIN, NJ

Financials · FY2025

Revenue$1.41M
Net income$-62.42M
Total debt$967.11M
Cash$7.75M
Diluted EPS$-1.79
Shares outstanding120.9M

Ownership

120.9M shares outstanding · as of May 12, 2026
0.36%Insiders
Ownership
Insiders0.36%429,248
Institutions7.76%9,374,933
Public float91.89%111,059,071

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 2

View all →
Insider% of sharesShares
Hilzinger Kurt JDirector
0.35%423,655
Thurman Randy HDirector
<0.01%5,593

Institutional holders 57

View all →
HolderValue% of shares
Schonfeld Strategic Advisors LLC$3.86M2.02%
BlackRock, Inc.$2.65M1.38%
Vanguard Group Inc$2.31M1.21%
State Street Corporation$858.3K0.45%
Gilpin Wealth Management, LLC$559.6K0.29%
Marshall Wace, LLP$471.6K0.25%
UBS Group AG$331.1K0.17%
LPL Financial LLC$294.1K0.15%
Susquehanna International Group, LLP$271.8K0.14%
Millennium Management LLC$259.9K0.14%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 26, 2026Hilzinger Kurt J
Director
BuyCommon Stock$176.5K+400K
+1690.97%
423,655
0.35% of shares
medium
May 26, 2026Thurman Randy H
Director
BuyCommon Stock$2.1K+5K
+843.17%
5,593
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Sphera Funds Management Ltd.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
OTLKCommon StockEquity69012T305BBG00469JRJ5